Xeris Biopharma Holdings
XERS
200 hedge funds and large institutions have $422M invested in Xeris Biopharma Holdings in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 78 increasing their positions, 59 reducing their positions, and 24 closing their positions.
165% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $384K
32% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 59
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
0.95% more ownership
Funds ownership: 56.9% → 57.85% (+0.95%)
1% more funds holding
Funds holding: 199 → 200 (+1)
12% less capital invested
Capital invested by funds: $481M → $422M (-$58.4M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.82M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.71M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$5.14M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.59M |
| 5 |
BlackRock
New York
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.18M |
| 2 |
JP Morgan Chase
New York
|
-$4.96M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.31M |
| 4 |
Jane Street
New York
|
-$3.62M |
| 5 |
Morgan Stanley
New York
|
-$2.96M |
XERS Hedge Fund Activity: Q2 2025 in Review
200 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2025, worth a combined $422M — down 12% from $481M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XERS positions and 24 closed out — a net gain of 2 holders — while 78 added to existing stakes and 59 trimmed.
The largest buyer was Vanguard Group, adding an estimated $7.82M. The largest seller was Citadel Advisors, exiting entirely with an estimated $6.18M sold.
- 200 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2025, up from 199 in Q1 2025.
- Funds reported $422M of Xeris Biopharma Holdings stock for Q2 2025, down 12% quarter-over-quarter.
- 26 funds opened new Xeris Biopharma Holdings positions in Q2 2025 and 24 closed out, a net change of +2 holders.
- The largest Xeris Biopharma Holdings buyer in Q2 2025 was Vanguard Group, an estimated $7.82M added.
- The largest Xeris Biopharma Holdings seller in Q2 2025 was Citadel Advisors, an estimated $6.18M sold.
Based on aggregated 13F filings for Q2 2025.